SCHEMBL5369280

SCHEMBL5369280

COCC(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.58
NPSR1 Q6W5P4 1/20 0.55
ALDH1A1 P00352 3/20 0.52
POLB P06746 2/20 0.52
ACHE P22303 1/20 0.51
SRD5A2 P31213 1/20 0.50
CTNNB1 P35222 1/20 0.50
WNT3A P56704 1/20 0.50
KMT2A Q03164 2/20 0.49
TAS1R3 Q7RTX0 1/20 0.49
TAS1R1 Q7RTX1 1/20 0.49
MEN1 O00255 1/20 0.49
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
LMNA P02545 1/20 0.48
HDAC3 O15379 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19707220 0.84 NPSR1 (0.56) CES2SMN1; SMN2NPSR1ALDH1A1POLB
SCHEMBL27343169 0.84 CES2 (0.56) CES2NPSR1ALDH1A1POLBACHE
SCHEMBL449754 0.83 NPSR1 (0.57) CES2SMN1; SMN2NPSR1ALDH1A1POLB
SCHEMBL7336597 0.83 CES2 (0.57) CES2NPSR1ALDH1A1POLBACHE
SCHEMBL2543135 0.82 CES2 (0.53) CES2SMN1; SMN2NPSR1ALDH1A1POLB
SCHEMBL716488 0.81 CES2 (0.65) CES2NPSR1ALDH1A1POLBACHE
SCHEMBL24239347 0.81 CES2 (0.56) CES2NPSR1ALDH1A1POLBACHE
SCHEMBL30758861 0.81 CES2 (0.69) CES2NPSR1ALDH1A1POLBACHE
SCHEMBL10960536 0.80 NPSR1 (0.55) CES2SMN1; SMN2NPSR1ALDH1A1POLB
SCHEMBL4420680 0.80 CTNNB1 (0.56) CES2SMN1; SMN2NPSR1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608217-B2 Process for producing 4-substituted benzopyran derivatives CENTRAL GLASS COMPANY, LIMITED (JP) 2003-08-19 US claimed
US-20030109574-A1 Process for producing 4-substituted benzopyran derivatives CENTRAL GLASS COMPANY, LIMITED (JP) 2003-06-12 US claimed
EP-1298129-A2 Process for producing 4-sustituted benzopyran derivatives Central Glass Company, Limited (JP) 2003-04-02 EP claimed
WO-2022023447-A2 FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) 2022-02-03 WO disclosed
EP-1546126-B1 PROCESS FOR PRODUCING TRIFLUOROMETHYL-SUBSTITUTED 2-ALKOXYACETOPHENONE DERIVATIVES CENTRAL GLASS CO LTD (JP) 2007-11-21 EP disclosed
CN-100347166-C Process for producing trifluoromethyl- substituted 2- alkoxyacetophenone derivatives CENTRAL GLASS CO LTD (JP) 2007-11-07 CN disclosed
US-7189863-B2 Process for producing trifluoromethyl-substituted 2-alkoxyacetophenone derivatives CENTRAL GLASS COMPANY, LIMITED (JP) 2007-03-13 US disclosed
US-20060128976-A1 Process for producing trifluoromethyl-substituted 2-alkoxyacetophenone derivatives CENTRAL GLASS COMPANY, LIMITED (JP) 2006-06-15 US disclosed
US-7053248-B2 brominating a trifluoromethyl-substituted acetophenone with bromine in presence of acetalization agent that is an alkylene diol, reacting the brominated acetal with metal alkoxide thereby converting brominated acetal into ether, hydrolyzing ether in presence of acid catalyst to remove an acetal group CENTRAL GLASS COMPANY, LIMITED (JP) 2006-05-30 US disclosed
CN-1671683-A Process for producing trifluoromethyl- substituted 2- alkoxyacetophenone derivatives CENTRAL GLASS CO LTD (JP) 2005-09-21 CN disclosed
US-20050171363-A1 Process for producing trifluoromethyl- substituted 2- alkoxyacetophenone derivatives CENTRAL GLASS COMPANY, LIMITED (JP) 2005-08-04 US disclosed
EP-1546126-A1 PROCESS FOR PRODUCING TRIFLUOROMETHYL-SUBSTITUTED 2-ALKOXYACETOPHENONE DERIVATIVES Central Glass Company, Limited (JP) 2005-06-29 EP disclosed
WO-2004014887-A1 PROCESS FOR PRODUCING TRIFLUOROMETHYL-SUBSTITUTED 2-ALKOXYACETOPHENONE DERIVATIVES CENTRAL GLASS COMPANY, LIMITED (JP) 2004-02-19 WO disclosed
US-6608217-B2 Process for producing 4-substituted benzopyran derivatives CENTRAL GLASS COMPANY, LIMITED (JP) 2003-08-19 US disclosed
US-20030109574-A1 Process for producing 4-substituted benzopyran derivatives CENTRAL GLASS COMPANY, LIMITED (JP) 2003-06-12 US disclosed
EP-1298129-A2 Process for producing 4-sustituted benzopyran derivatives Central Glass Company, Limited (JP) 2003-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109574-A1 Process for producing 4-substituted benzopyran derivatives ACSL4, HAO2, ACSL6 CES2 2045/4885SMN1; SMN2 4665/4885NPSR1 1615/4885
US-20060128976-A1 Process for producing trifluoromethyl-substituted 2-alkoxyacetophenone derivatives HACL2, BOLA2; BOLA2B, ADH5 CES2 148/4885SMN1; SMN2 4155/4885NPSR1 4832/4885
US-20050171363-A1 Process for producing trifluoromethyl- substituted 2- alkoxyacetophenone derivatives HACL2, BOLA2; BOLA2B, ADH5 CES2 148/4885SMN1; SMN2 4155/4885NPSR1 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.